Skip to content

Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients

Evaluation of an Oral Nutritional Supplement Containing AN 777 in Older Hospitalized Patients

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01477723
Enrollment
17
Registered
2011-11-22
Start date
2011-10-31
Completion date
2012-11-30
Last updated
2013-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Brief summary

Study objectives are to verify the loss of lean mass during a hospital stay in a group of older patients; to evaluate the effects of consuming a high-calorie complete and balanced oral nutritional supplement; to collect post-discharge information.

Interventions

OTHERExperimental Oral Nutritional Supplement

Experimental ONS orally Two 8 fl oz servings/day

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. ≥ 55 years of age. 2. Admitted to hospital with a disease of respiratory system including acute respiratory diseases (e.g., pneumonia, acute bronchitis) or exacerbation of existing respiratory diseases. 3. Anticipated length of hospital stay of at least 3 days. 4. Ability to climb a flight of 10 stairs or walk a city block without the help of another person prior to hospitalization. 5. Able to consume foods and beverages orally.

Exclusion criteria

1. Unstable heart failure which requires ICU admission. 2. Severe respiratory disease requiring long-term, continuous oxygen therapy. 3. Diabetes. 4. Impaired renal function. 5. Impaired liver function. 6. Cancer. 7. Hospitalized for two or more days in past 4 weeks. 8. Requires intubation or tube feeding. 9. Expected to be transferred to an advanced care unit. 10. Body mass index of ≥ 40 kg/m2. 11. Active tuberculosis. 12. Ascites or severe edema. 13. Acute Hepatitis or HIV. 14. Disorder of gastrointestinal tract. 15. Dementia;brain metastases, eating disorder, significant neurological, psychiatric disorder, other psychological condition. 16. Medication/dietary supplements/substances that could modulate metabolism or weight. 17. Partial or full artificial lower limb. 18. Allergy or intolerance to any of the ingredients in the study products. 19. Procedure using iodine-based contrast media within 7 days prior to hospitalization; or, anticipated to need procedure using iodine-based contrast media within 3 days after hospital admission.

Design outcomes

Primary

MeasureTime frame
Leg Lean Massbaseline to day 30

Secondary

MeasureTime frame
Body Weightbaseline to day 30
Body Mass Indexbaseline to day 30
Activities of daily livingbaseline to day 30

Countries

Puerto Rico, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026